title: Antiviral treatment of Coxsackie B virus infection in human pancreatic islets.
abstract: Enterovirus infections of the pancreatic islets are believed to trigger or precipitate the near total destruction of beta-cells that constitutes type 1 diabetes (T1D). This study investigated the ability of an anti-picornaviral compound, pleconaril, to block the replication of two beta-cell tropic Coxsackie B4 virus (CBV-4) strains in isolated human islets. The two strains, VD2921 and V89 4557, with demonstrated abilities to cause non-lytic persistence or lytic infection, respectively, in islets, represented two different potential mechanisms behind virus-induced T1D. The virus replication in the islets was studied with and without addition of pleconaril. In addition, islet morphology was studied every day. To test the effects of pleconaril and/or DMSO on the beta-cells' insulin secretion, glucose perifusions were performed on treated and untreated islets. Virus titrations showed a clear reduction of the replication of both strains after pleconaril treatment. The VD2921 strain was inhibited to undetectable levels. The V89 4557 strain, however, showed an initial reduction of titers but virus titers then increased despite the addition of a second dose of pleconaril. This incomplete inhibition of viral replication suggested the existence of a resistant subtype within this strain. Pleconaril treatment reduced the beta-cells' insulin secretion in response to glucose stimulation in some experiments and induced slight morphological changes to the islets compared to untreated controls. In summary, pleconaril reduced the replication of the two beta-cell tropic CBV-4 strains in human islets. However, genetic differences between these strains influenced the effectiveness of pleconaril treatment. This stresses the importance of using multiple viral strains in antiviral tests.
authors.affiliation: Department of Women's and Children's Health, Uppsala University, Akademiska Hospital, ing 95/96 nbv, SE-751 85 Uppsala, Sweden. Anna-Karin.Berg@kbh.uu.se
authors.forename: Anna-Karin
authors.initials: AK
authors.lastname: Berg
authors.forename: Annika
authors.initials: A
authors.lastname: Olsson
authors.forename: Olle
authors.initials: O
authors.lastname: Korsgren
authors.forename: Gun
authors.initials: G
authors.lastname: Frisk
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D003384:Coxsackievirus Infections / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D003588:Cytopathogenic Effect, Viral / Q000187:drug effects; D003922:Diabetes Mellitus, Type 1 / Q000821:virology; D029822:Enterovirus B, Human / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007328:Insulin / Q000032:analysis / Q000378:metabolism; D007515:Islets of Langerhans / Q000378:metabolism / Q000473:pathology / Q000821:virology; D010069:Oxadiazoles / Q000494:pharmacology*; D010080:Oxazoles
chemical_list: D000998:Antiviral Agents; D007328:Insulin; D010069:Oxadiazoles; D010080:Oxazoles; C115201:pleconaril